Chromocell Therapeutics (Chromocell Therapeutics) Change In Inventory : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Chromocell Therapeutics Change In Inventory?

Chromocell Therapeutics's change in inventory for the quarter that ended in Mar. 2024 was $0.00 Mil. It means Chromocell Therapeutics's inventory stayed the same from Dec. 2023 to Mar. 2024 .

Chromocell Therapeutics's change in inventory for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Chromocell Therapeutics's inventory stayed the same from Dec. 2022 to Dec. 2023 .

Chromocell Therapeutics's Total Inventories for the quarter that ended in Mar. 2024 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Chromocell Therapeutics Change In Inventory Historical Data

The historical data trend for Chromocell Therapeutics's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chromocell Therapeutics Change In Inventory Chart

Chromocell Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Change In Inventory

Chromocell Therapeutics Quarterly Data
	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Inventory	Get a 7-Day Free Trial							-	-	-	-	-

Chromocell Therapeutics Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Chromocell Therapeutics (AMEX:CHRO) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Chromocell Therapeutics's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Chromocell Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Chromocell Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=	N/A

Chromocell Therapeutics Change In Inventory Related Terms

Thank you for viewing the detailed overview of Chromocell Therapeutics's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Chromocell Therapeutics (Chromocell Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chromocell Therapeutics Corp (AMEX:CHRO) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Chromocell Therapeutics Corp is a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Its clinical focus is to selectively target the sodium ion-channel known as "NaV1.7", as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology.